Breaking News Instant updates and real-time market news.

NXPI

NXP Semiconductors

$102.50

-0.73 (-0.71%)

, QCOM

Qualcomm

$66.84

0.16 (0.24%)

14:06
10/06/16
10/06
14:06
10/06/16
14:06

NXP prefers all-cash offer from Qualcomm as sides narrow gap, Bloomberg says

NXPI

NXP Semiconductors

$102.50

-0.73 (-0.71%)

QCOM

Qualcomm

$66.84

0.16 (0.24%)

  • 13

    Mar

NXPI NXP Semiconductors
$102.50

-0.73 (-0.71%)

09/30/16
RHCO
09/30/16
NO CHANGE
RHCO
NXP Semiconductors could be acquired for $124 per share, says SunTrust
After Dow Jones reported that NXP (NXPI) is in talks to be bought by Qualcomm (QCOM) for more than $95 per share, SunTrust analyst William Stein says that, based on recent takeover valuations in the semiconductor space, NXP would be acquired for $124 per share. The analyst says that NXP is worth $104 per share on a standalone basis, and he does not expect the company to sell itself for $95. Stein adds that NXP would improve Qualcomm's efforts in NFC and automotive. He expects NXP's stock to rise whether or not a deal is made, and he keeps a Buy rating on the shares.
09/30/16
OPCO
09/30/16
NO CHANGE
OPCO
NXP 'cheap' for Qualcomm even after rally, says Oppenheimer
Oppenheimer analyst Rick Schafer says NXP Semiconductors (NXPI) still a "cheap" takeover target for Qualcomm (QCOM) even after rallying 25% over the past two days. An acquisition would be accretive to Qualcomm's earnings "under most scenarios," the analyst tells investors in an intraday research note. He thinks Qualcomm needs to diversify away from handsets and has $31B of offshore cash, the analyst contends. Schafer keeps a Perform rating on Qualcomm.
10/03/16
UBSW
10/03/16
NO CHANGE
Target $59
UBSW
Neutral
Qualcomm acquisition of NXP Semiconductors would be positive, says UBS
UBS analyst Stephen Chin said he would view an acquisition of NXP Semiconductors (NXPI) by Qualcomm (QCOM) as positive citing such a deals likely accretion, as well as benefits like sales diversification, its patent portfolio and cash flow generation. Chin maintains his Neutral rating and $59 price target on Qualcomm shares.
10/03/16
RBCM
10/03/16
NO CHANGE
Target $70
RBCM
Sector Perform
RBC says $120-130/share seems like high end of reasonable Qualcomm price for NXP
RBC analyst Amit Daryanani believes $120-$130 per share is likely the "upper end of the valuation framework" that Qualcomm (QCOM) would like to pay in any potential deal to acquire NXP Semiconductors (NXPI). While Qualcomm "can certainly elect to pay a larger premium" than that, doing so would likely come in the form of Qualcomm equity issuance, which would impede the accretion from the deal, Daryanani tells investors. The analyst keeps a Sector Perform rating on Qualcomm shares, but raised his price target on the stock to $70 from $59 citing the potential for diversification and higher cash flow generation that an NXP deal would provide.
QCOM Qualcomm
$66.84

0.16 (0.24%)

09/30/16
09/30/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Qualcomm (QCOM) upgraded on potential NXP Semiconductors acquisition at Mizuho with the firm's analyst saying he believes a Qualcomm acquisition of NXP Semiconductors (NXPI) makes significant strategic and financial sense. 2. Skechers (SKX) upgraded to Positive from Neutral at Susquehanna. 3. Sprouts Farmers Markets (SFM) upgraded to Buy from Hold at Jefferies with analyst Christopher Mandeville saying the risk/reward is now favorable following the recent pullback in the shares. 4. Phillips 66 (PSX) upgraded to Neutral from Sell at Goldman with analyst Neil Mehta citing higher multiple assumptions for midstream and chemicals segments, reduced capex spending and higher free cash flow estimates, and more achievable consensus expectations. 5. NetApp (NTAP) upgraded to Buy from Sell at Summit Redstone with analyst Srini Nandury citing optimism that the company can grow its product revenue from current levels driven by AFA sales and increasing adoption of clustered ONTAP. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

SLV

iShares Silver Trust

$17.41

0.17 (0.99%)

12:11
02/24/17
02/24
12:11
02/24/17
12:11
Options
Sizable four-way spread in the Silver Fund as a bullish option play is adjusted »

Sizable four-way spread…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FNB

F.N.B.

$15.52

-0.15 (-0.96%)

, YDKN

Yadkin Financial

$33.15

-0.415 (-1.24%)

12:03
02/24/17
02/24
12:03
02/24/17
12:03
Periodicals
Federal Reserve clears F.N.B.'s takeover of Yadkin, Reuters reports »

The Federal Reserve has…

FNB

F.N.B.

$15.52

-0.15 (-0.96%)

YDKN

Yadkin Financial

$33.15

-0.415 (-1.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVDA

NVIDIA

$100.49

-10.27 (-9.27%)

12:01
02/24/17
02/24
12:01
02/24/17
12:01
Options
Heavy trading in Nvidia short-term options as shares stage an aggressive rebound »

Heavy trading in Nvidia…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 05

    Mar

  • 16

    Mar

  • 20

    Mar

12:00
02/24/17
02/24
12:00
02/24/17
12:00
General news
Treasury Option Action: a round of put activity »

Treasury Option Action: a…

ONCS

OncoSec

$1.42

-0.1 (-6.58%)

11:59
02/24/17
02/24
11:59
02/24/17
11:59
Conference/Events
OncoSec to hold KOL Event Focused on New ASCO-SITC Melanoma Data »

OncoSec's Chief…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGEN

Miragen Therapeutics

$13.99

-0.06 (-0.43%)

11:55
02/24/17
02/24
11:55
02/24/17
11:55
Hot Stocks
Boulder Ventures V reports 9.9% stake in Miragen Therapeutics »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTG

MGIC Investment

$10.55

-0.055 (-0.52%)

11:51
02/24/17
02/24
11:51
02/24/17
11:51
Options
MGIC Investment with 11.5X average daily optoin volume driven by a bullish play »

MGIC Investment with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WLL

Whiting Petroleum

$11.06

-0.09 (-0.81%)

11:46
02/24/17
02/24
11:46
02/24/17
11:46
Options
Whiting Petroleum call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

11:45
02/24/17
02/24
11:45
02/24/17
11:45
Conference/Events
Leerink analysts hold an analyst/industry conference call »

In conjunction with the…

11:40
02/24/17
02/24
11:40
02/24/17
11:40
General news
NY Fed Nowcast has Q1 GDP at 3.12% »

NY Fed Nowcast has Q1 GDP…

SPWR

SunPower

$8.99

0.53 (6.26%)

11:36
02/24/17
02/24
11:36
02/24/17
11:36
Options
SunPower put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IDRA

Idera Pharmaceuticals

$1.73

0.05 (2.98%)

11:33
02/24/17
02/24
11:33
02/24/17
11:33
Hot Stocks
Idera says achieved 'successful' completion of objectives in Phase 1 trial »

Idera Pharmaceuticals is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRIL

Trillium Therapeutics

$5.90

-0.1 (-1.67%)

11:32
02/24/17
02/24
11:32
02/24/17
11:32
Hot Stocks
Trillium Therapeutics: New TTI-621 data advances understanding of product »

Trillium Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VISI

Volt Information Sciences

$7.35

-0.1 (-1.34%)

, CCRN

Cross Country Healthcare

$15.89

-0.37 (-2.28%)

11:32
02/24/17
02/24
11:32
02/24/17
11:32
Hot Stocks
Volt Information Sciences reports nomination of new independent directors »

Volt Information Sciences…

VISI

Volt Information Sciences

$7.35

-0.1 (-1.34%)

CCRN

Cross Country Healthcare

$15.89

-0.37 (-2.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

  • 08

    Mar

  • 14

    Mar

  • 21

    Mar

MCO

Moody's

$112.59

-0.64 (-0.57%)

11:31
02/24/17
02/24
11:31
02/24/17
11:31
Conference/Events
Leerink analysts hold an analyst/industry conference call »

Analysts provide a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

  • 05

    Mar

VIVHY

Vivendi

$17.95

-0.06 (-0.33%)

, MDIUY

Mediaset

11:28
02/24/17
02/24
11:28
02/24/17
11:28
Periodicals
Milan prosecutors investigating Vivendi over alleged stock manipulation, FT says »

Milan prosecutors are…

VIVHY

Vivendi

$17.95

-0.06 (-0.33%)

MDIUY

Mediaset

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FSLR

First Solar

$37.19

3.62 (10.78%)

11:26
02/24/17
02/24
11:26
02/24/17
11:26
Options
First Solar call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Mar

GS

Goldman Sachs

$247.19

-4 (-1.59%)

11:23
02/24/17
02/24
11:23
02/24/17
11:23
Periodicals
Goldman Sachs exec involved in 1MDB dealings leaves bank, WSJ says »

A senior Goldman Sachs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

ALNY

Alnylam

$46.25

0.3 (0.65%)

11:22
02/24/17
02/24
11:22
02/24/17
11:22
Conference/Events
JPMorgan SMid biotech analyst holds an analyst/industry conference call »

SMid Biotech Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

$NSD

NASDAQ Market Internals

11:17
02/24/17
02/24
11:17
02/24/17
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

11:16
02/24/17
02/24
11:16
02/24/17
11:16
Technical Analysis
NYSE market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MBLY

Mobileye

$46.96

-1.18 (-2.45%)

11:16
02/24/17
02/24
11:16
02/24/17
11:16
Options
Mobileye put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

HBI

Hanesbrands

$20.96

0.04 (0.19%)

11:12
02/24/17
02/24
11:12
02/24/17
11:12
Conference/Events
Hanesbrands management to meet with Oppenheimer »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

WIX

Wix.com

$63.25

-2.3 (-3.51%)

11:10
02/24/17
02/24
11:10
02/24/17
11:10
Conference/Events
Wix.com management to meet with Oppenheimer »

Meetings to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 01

    Mar

  • 02

    Mar

SNCR

Synchronoss

$30.86

-0.03 (-0.10%)

11:09
02/24/17
02/24
11:09
02/24/17
11:09
Periodicals
Synchronoss has withheld 'a great deal' about 'transformation,' SIRF says »

Synchronoss Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.